Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2015, Article ID 740815, 8 pages
http://dx.doi.org/10.1155/2015/740815
Research Article

Discovery of Specific Inhibitors for Intestinal E. coli  β-Glucuronidase through In Silico Virtual Screening

1Graduate Institute of Pharmacognosy, Taipei Medical University, 252 Wu Hsing Street, Taipei 11031, Taiwan
2Institute of Biomedical Sciences, Academia Sinica, 128 Section 2, Academia Road, Nankang, Taipei 11529, Taiwan
3Institute of Biomedical Science, 70 Lienhai Road, Kaohsiung 80424, National Sun Yat-Sen University, Taiwan
4Department of Pharmacy, Chia Nan University of Pharmacy and Science, 60 Section 1, Erh-Ren Road, Tainan 71710, Taiwan
5Department of Biomedical and Environmental Biology, Kaohsiung Medical University, 100 Shih-Chuan 1st Road, Kaohsiung 80708, Taiwan
6Graduate Institute of Medicine, Kaohsiung Medical University, 100 Shih-Chuan 1st Road, Kaohsiung 80708, Taiwan
7Center for Biomarkers and Biotech Drugs, Kaohsiung Medical University, 100 Shih-Chuan 1st Road, Kaohsiung 80708, Taiwan
8School of Pharmacy, China Medical University, 91 Hsueh-Shih Road, Taichung 40402, Taiwan

Received 15 August 2014; Accepted 27 August 2014

Academic Editor: Li-Yeh Chuang

Copyright © 2015 Ta-Chun Cheng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. M. Nelson, A. E. Swank, L. R. Brooks, K. C. Bailey, and S. E. George, “Metabolism, microflora effects, and genotoxicity in haloacetic acid-treated cultures of rat cecal microbiota,” Toxicological Sciences, vol. 60, no. 2, pp. 232–241, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. I. Rowland, “The influence of the gut microflora on food toxicity,” Proceedings of the Nutrition Society, vol. 40, no. 1, pp. 67–74, 1981. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Humblot, M. Murkovic, L. Rigottier-Gois et al., “β-glucuronidase in human intestinal microbiota is necessary for the colonic genotoxicity of the food-borne carcinogen 2-amino-3-methylimidazo[4,5-f]quinoline in rats,” Carcinogenesis, vol. 28, no. 11, pp. 2419–2425, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Rowland, J. O. Miners, and P. I. Mackenzie, “The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification,” International Journal of Biochemistry and Cell Biology, vol. 45, no. 6, pp. 1121–1132, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. K. Takasuna, T. Hagiwara, K. Watanabe et al., “Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea,” Cancer Chemotherapy and Pharmacology, vol. 58, no. 4, pp. 494–503, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Chihara, K. Shimpo, T. Kaneko et al., “Inhibition of 1, 2-dimethylhydrazine-induced mucin-depleted foci and O6-methylguanine DNA adducts in the rat colorectum by boiled garlic powder,” Asian Pacific Journal of Cancer Prevention, vol. 11, no. 5, pp. 1301–1304, 2010. View at Google Scholar · View at Scopus
  7. P. M. Kim and P. G. Wells, “Genoprotection by UDP-glucuronosyltransferases in peroxidase-dependent, reactive oxygen species-mediated micronucleus initiation by the carcinogens 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and benzo[a]pyrene,” Cancer Research, vol. 56, no. 7, pp. 1526–1532, 1996. View at Google Scholar · View at Scopus
  8. M. Kim, S. Miyamoto, S. Sugie et al., “A tobacco-specific carcinogen, NNK, enhances AOM/DSS-induced colon carcinogenesis in male A/J mice,” In Vivo, vol. 22, no. 5, pp. 557–564, 2008. View at Google Scholar · View at Scopus
  9. K. R. Kaderlik, R. F. Minchin, G. J. Mulder et al., “Metabolic activation pathway for the formation of DNA adducts of the carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in rat extrahepatic tissues,” Carcinogenesis, vol. 15, no. 8, pp. 1703–1709, 1994. View at Publisher · View at Google Scholar · View at Scopus
  10. N. Nalini, V. Manju, and V. P. Menon, “Effect of coconut cake on the bacterial enzyme activity in 1,2-dimethyl hydrazine induced colon cancer,” Clinica Chimica Acta, vol. 342, no. 1-2, pp. 203–210, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. N. Nalini, K. Sabitha, P. Viswanathan, and V. P. Menon, “Influence of spices on the bacterial (enzyme) activity in experimental colon cancer,” Journal of Ethnopharmacology, vol. 62, no. 1, pp. 15–24, 1998. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Likhachev, V. Anisimov, L. Paranova, and K. Pozharisski, “Effect of exogenous β-glucuronidase on the carcinogenicity of 1,2-dimethylhydrazine in rats: evidence that carcinogenic intermediates form conjugates and act through their subsequent enzymatic release,” Carcinogenesis, vol. 6, no. 5, pp. 679–681, 1985. View at Publisher · View at Google Scholar · View at Scopus
  13. S. N. Newaz, W. F. Fang, and H. W. Strobel, “Metabolism of the carcinogen 1,2-dimethylhydrazine by isolated human colon microsomes and human colon tumor cells in culture,” Cancer, vol. 52, no. 5, pp. 794–798, 1983. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Wolter and N. Frank, “Metabolism of 1,2-dimethylhydrazine in isolated perfused rat liver,” Chemico-Biological Interactions, vol. 42, no. 3, pp. 335–344, 1982. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Kobayashi, “Chemotherapy-induced diarrhea,” Gan To Kagaku Ryoho, vol. 30, no. 6, pp. 765–771, 2003. View at Google Scholar · View at Scopus
  16. B. D. Wallace, H. Wang, K. T. Lane et al., “Alleviating cancer drug toxicity by inhibiting a bacterial enzyme,” Science, vol. 330, no. 6005, pp. 831–835, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. A. B. Roberts, B. D. Wallace, M. K. Venkatesh, S. Mani, and M. R. Redinbo, “Molecular insights into microbial β-glucuronidase inhibition to abrogate CPT-11 toxicity,” Molecular Pharmacology, vol. 84, no. 2, pp. 208–217, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Cascinu, E. Bichisao, D. Amadori et al., “High-dose loperamide in the treatment of 5-fluorouracil-induced diarrhea in colorectal cancer patients,” Supportive Care in Cancer, vol. 8, no. 1, pp. 65–67, 2000. View at Google Scholar · View at Scopus
  19. G. Dranitsaris, J. Maroun, and A. Shah, “Severe chemotherapy-induced diarrhea in patients with colorectal cancer: a cost of illness analysis,” Supportive Care in Cancer, vol. 13, no. 5, pp. 318–324, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Fittkau, W. Voigt, H.-J. Holzhausen, and H.-J. Schmoll, “Saccharic acid 1.4-lactone protects against CPT-11-induced mucosa damage in rats,” Journal of Cancer Research and Clinical Oncology, vol. 130, no. 7, pp. 388–394, 2004. View at Google Scholar · View at Scopus
  21. G. Constantopoulos, S. Rees, B. G. Cragg, J. A. Barranger, and R. O. Brady, “Experimental animal model for mucopolysaccharidosis: suramin-induced glycosaminoglycan and sphingolipid accumulation in the rat,” Proceedings of the National Academy of Sciences of the United States of America, vol. 77, no. 6, pp. 3700–3704, 1980. View at Publisher · View at Google Scholar · View at Scopus
  22. P. M. Gillett, R. A. Schreiber, G. P. Jevon et al., “Mucopolysaccharidosis type VII (Sly syndrome) presenting as neonatal cholestasis with hepatosplenomegaly,” Journal of Pediatric Gastroenterology and Nutrition, vol. 33, no. 2, pp. 216–220, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Ahmad, M. A. Hughes, L.-A. Yeh, and J. E. Scott, “Potential repurposing of known drugs as potent bacterial β-glucuronidase inhibitors,” Journal of Biomolecular Screening, vol. 17, no. 7, pp. 957–965, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. R. Kong, T. Liu, X. Zhu et al., “Old drug new use—amoxapine and its metabolites as potent bacterial β-glucuronidase inhibitors for alleviating cancer drug toxicity,” Clinical Cancer Research, vol. 20, no. 13, pp. 3521–3530, 2014. View at Publisher · View at Google Scholar
  25. I. D. Kuntz, “Structure-based strategies for drug design and discovery,” Science, vol. 257, no. 5073, pp. 1078–1082, 1992. View at Publisher · View at Google Scholar · View at Scopus
  26. E. C. Meng, B. K. Shoichet, and I. D. Kuntz, “Automated docking with grid-based energy evaluation,” Journal of Computational Chemistry, vol. 13, no. 4, pp. 505–524, 1992. View at Google Scholar
  27. T.-L. Cheng, B.-M. Chen, L.-Y. Chan, P.-Y. Wu, J.-W. Chern, and S. R. Roffler, “Poly(ethylene glycol) modification of β-glucuronidase-antibody conjugates for solid-tumor therapy by targeted activation of glucuronide prodrugs,” Cancer Immunology Immunotherapy, vol. 44, no. 6, pp. 305–315, 1997. View at Publisher · View at Google Scholar · View at Scopus
  28. G. Jones, P. Willett, R. C. Glen, A. R. Leach, and R. Taylor, “Development and validation of a genetic algorithm for flexible docking,” Journal of Molecular Biology, vol. 267, no. 3, pp. 727–748, 1997. View at Publisher · View at Google Scholar · View at Scopus
  29. N. C. Cohen, J. M. Blaney, C. Humblet, P. Gund, and D. C. Barry, “Molecular modeling software and methods for medicinal chemistry,” Journal of Medicinal Chemistry, vol. 33, no. 3, pp. 883–894, 1990. View at Publisher · View at Google Scholar · View at Scopus
  30. E. T. Maggio and K. Ramnarayan, “Recent developments in computational proteomics,” Drug Discovery Today, vol. 6, no. 19, pp. 996–1004, 2001. View at Publisher · View at Google Scholar · View at Scopus
  31. Y.-C. Su, K.-H. Chuang, Y.-M. Wang et al., “Gene expression imaging by enzymatic catalysis of a fluorescent probe via membrane-anchored β-glucuronidase,” Gene Therapy, vol. 14, no. 7, pp. 565–574, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. Y.-L. Leu, S. R. Roffler, and J.-W. Chern, “Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT),” Journal of Medicinal Chemistry, vol. 42, no. 18, pp. 3623–3628, 1999. View at Publisher · View at Google Scholar · View at Scopus
  33. A. W. Wong, S. He, J. H. Grubb, W. S. Sly, and S. G. Withers, “Identification of Glu-540 as the catalytic nucleophile of human β- glucuronidase using electrospray mass spectrometry,” The Journal of Biological Chemistry, vol. 273, no. 51, pp. 34057–34062, 1998. View at Publisher · View at Google Scholar · View at Scopus
  34. T. Legigan, J. Clarhaut, B. Renoux et al., “Synthesis and antitumor efficacy of a β-glucuronidase-responsive albumin-binding prodrug of doxorubicin,” Journal of Medicinal Chemistry, vol. 55, no. 9, pp. 4516–4520, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. T.-C. Cheng, S. R. Roffler, S.-C. Tzou et al., “An activity-based near-infrared glucuronide trapping probe for imaging β-glucuronidase expression in deep tissues,” Journal of the American Chemical Society, vol. 134, no. 6, pp. 3103–3110, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Stein, W. Voigt, and K. Jordan, “Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management,” Therapeutic Advances in Medical Oncology, vol. 2, no. 1, pp. 51–63, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. D.-H. Kim and Y.-H. Jin, “Intestinal bacterial β-glucuronidase activity of patients with colon cancer,” Archives of Pharmacal Research, vol. 24, no. 6, pp. 564–567, 2001. View at Publisher · View at Google Scholar · View at Scopus